secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2026-05-13T20:10:20+00:00
Accession:  0001493152-26-022721
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iMDx reports Q1 net loss $4.3M; signs first GALACTIC trial site, advances FDA submission
--------------------------------------------------------------------------------

- Q1 revenue ~$32K, gross profit $15K; net loss $4.3M ($0.12/share); non-GAAP net loss $9.6M ($0.28/share).
- Signed first clinical trial agreement for GALACTIC registry with a top-10 U.S. kidney transplant center.
- Non-GAAP operating expenses $4.4M including $5.9M non-cash gain; R&D down 15% sequentially.
- Expect FDA marketing authorization for GraftAssureDx later 2026; productive FDA dialogue ongoing.
- Small RUO orders from Switzerland and pending from Southeast Asia; first U.S. orders anticipated later this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315226022721/0001493152-26-022721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315226022721/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer